Thalidomide, a novel immunological treatment to modify the natural history of paediatric Crohn's disease: a new proposal from a well-established paediatric research network (Talidomide: un nuovo trattamento immunologico per modificare la storia naturale del morbo di Crohn a esordio pediatrico: una nuova proposta da un gruppo di ricerca pediatrico consolidato)

Trial Profile

Thalidomide, a novel immunological treatment to modify the natural history of paediatric Crohn's disease: a new proposal from a well-established paediatric research network (Talidomide: un nuovo trattamento immunologico per modificare la storia naturale del morbo di Crohn a esordio pediatrico: una nuova proposta da un gruppo di ricerca pediatrico consolidato)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Thalidomide (Primary) ; Infliximab
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top